Most Recent
Judge warns ‘enough’s enough’ in fight for damages over delayed Abilify generic
Intellectual Property 2021-06-03 10:52 am By Cat Fredenburgh

A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the delayed launch of generic versions of their antipsychotic drug Abilify, but warned there had to be a cut-off point for preparing the decade-long dispute for trial.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Otsuka ‘deliberately’ withheld information from court, Generic Health claims
Intellectual Property 2019-09-17 9:30 pm By Miklos Bolza

Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb “deliberately” chose not to disclose their reasons for an admission in a long-running patent case over the anti-psychotic drug Abilify, which they are now seeking to withdraw.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.